Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $156
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Novo Nordisk Analyst Ratings
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Why Eli Lilly Is a Buy After Earnings. The Stock Got an Upgrade. -- Barrons.com